Deciphera's Vimseltinib Study Evaluates Interaction with Oral Contraceptives
A clinical trial is underway to assess how vimseltinib affects the pharmacokinetics of a combined oral contraceptive.
Phase III
Oncology / Small Molecule
Status
Active
Sponsor
Deciphera Pharmaceuticals, LLC
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial evaluating vimseltinib's interaction with oral contraceptives is significant as it may influence prescribing practices and patient safety. The results could lead to changes in labeling, impacting the drug's market adoption and competitive positioning.
Recommended action
Humanexa recommends Monitor: Monitoring is recommended to stay informed about trial outcomes and any subsequent changes to prescribing information, which could affect clinical adoption and market dynamics.
Analysis
Monitor for trial results and any subsequent changes to vimseltinib's prescribing information.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.